Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study

Lymphomas are not infrequently associated with the Epstein-Barr virus (EBV), and EBV positivity is linked to worse outcomes in several subtypes. Nanatinostat is a class-I selective oral histone deacetylase inhibitor that induces the expression of lytic EBV BGLF4 protein kinase in EBV(+) tumor cells,...

Descripción completa

Detalles Bibliográficos
Autores principales: Haverkos, Bradley, Alpdogan, Onder, Baiocchi, Robert, Brammer, Jonathan E., Feldman, Tatyana A., Capra, Marcelo, Brem, Elizabeth A., Nair, Santosh, Scheinberg, Phillip, Pereira, Juliana, Shune, Leyla, Joffe, Erel, Young, Patricia, Spruill, Susan, Katkov, Afton, McRae, Robert, Royston, Ivor, Faller, Douglas V., Rojkjaer, Lisa, Porcu, Pierluigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587711/
https://www.ncbi.nlm.nih.gov/pubmed/37530631
http://dx.doi.org/10.1182/bloodadvances.2023010330

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587711/
https://www.ncbi.nlm.nih.gov/pubmed/37530631
http://dx.doi.org/10.1182/bloodadvances.2023010330

Ejemplares similares